This Genetic Technology TOE depicts life sciences trends across cystic fibrosis. First-in class mRNA therapeutics with targeted delivery, novel cell types, lentiviral gene therapy, and RNA vaccines, among other therapies are profiled. Clinical trials of RNA vaccines for the cancer treatment are also depicted.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions.
The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: mRNA therapeutics, targeted delivery, cell types, lentiviral gene therapy, RNA vaccines
Table of Contents
Recent Advances in Development of Novel Treatments for Cystic Fibrosis
- A First-in Class mRNA Therapeutic With Targeted Delivery
- Novel Cell Type that Can Revolutionize Cystic Fibrosis Treatment
- Collaborative Development of Lentiviral Gene Therapy
- Treating Pulmonary Exacerbations in Cystic Fibrosis patients
Clinical Trial Analysis and Key Contacts
- Clinical Trial Analysis of RNA Vaccines for the Treatment of Cancer
- Key Contacts
